The virus-induced signaling adaptor molecule enhances DNA-raised immune protection against H5N1 influenza virus infection in mice
- PMID: 21303708
- DOI: 10.1016/j.vaccine.2011.01.060
The virus-induced signaling adaptor molecule enhances DNA-raised immune protection against H5N1 influenza virus infection in mice
Abstract
As an adaptor molecule in the retinoic acid-inducible gene-I (RIG-I) signaling pathway, the virus-induced signaling adaptor (VISA) molecule activates NF-κB and IRF3 and thereby leads to the production of type I interferons (IFNs). To explore the potential of VISA as a genetic adjuvant for DNA vaccines, a eukaryotic expression plasmid, pVISA, was generated by cloning the VISA gene into the pVAX1vector. For comparison, the pTRIF plasmid was similarly constructed, encoding the known genetic adjuvant TRIF (TIR-domain-containing adapter-inducing interferon-β), an adapter in the Toll-like receptor (TLR) signaling pathway. Mice were immunized with the chimeric DNA vaccine pHA/NP(147-155), which encodes the HA (hemagglutinin) fused with NP (nucleoprotein) CTL epitope (NP(147-155)) of H5N1 influenza virus, either alone or in combination with pVISA or pTRIF. Antigen-specific immune responses were examined in immunized mice. Our results demonstrate that co-immunization of the pHA/NP(147-155) plasmid with the VISA adjuvant augmented DNA-raised cellular immune responses and provided protection against H5N1 influenza virus challenge in mice. In addition, our data suggest that VISA acts as a stronger adjuvant for DNA immunization than TRIF. We conclude that co-inoculation with a vector expressing the adaptor molecule VISA enhanced the protective immunity against H5N1 infection induced by pHA/NP(147-155) and that VISA could be developed as a novel genetic adjuvant for DNA vaccines.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.J Virol Methods. 2008 Dec;154(1-2):121-7. doi: 10.1016/j.jviromet.2008.08.011. Epub 2008 Sep 27. J Virol Methods. 2008. PMID: 18789973
-
Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.Antiviral Res. 2009 Mar;81(3):253-60. doi: 10.1016/j.antiviral.2008.12.009. Epub 2009 Jan 9. Antiviral Res. 2009. PMID: 19135483
-
Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.Vaccine. 2012 Jan 11;30(3):626-36. doi: 10.1016/j.vaccine.2011.11.017. Epub 2011 Nov 23. Vaccine. 2012. PMID: 22119588
-
Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins.Jpn J Infect Dis. 2000 Dec;53(6):219-28. Jpn J Infect Dis. 2000. PMID: 11227019 Review.
-
Progress on adenovirus-vectored universal influenza vaccines.Hum Vaccin Immunother. 2015;11(5):1209-22. doi: 10.1080/21645515.2015.1016674. Hum Vaccin Immunother. 2015. PMID: 25876176 Free PMC article. Review.
Cited by
-
DNA Vaccines-How Far From Clinical Use?Int J Mol Sci. 2018 Nov 15;19(11):3605. doi: 10.3390/ijms19113605. Int J Mol Sci. 2018. PMID: 30445702 Free PMC article. Review.
-
The impact of immuno-aging on SARS-CoV-2 vaccine development.Geroscience. 2021 Feb;43(1):31-51. doi: 10.1007/s11357-021-00323-3. Epub 2021 Feb 11. Geroscience. 2021. PMID: 33569701 Free PMC article. Review.
-
Innate signalling molecules as genetic adjuvants do not alter the efficacy of a DNA-based influenza A vaccine.PLoS One. 2020 Apr 3;15(4):e0231138. doi: 10.1371/journal.pone.0231138. eCollection 2020. PLoS One. 2020. PMID: 32243477 Free PMC article.
-
Conserved Functions of Orthohepadnavirus X Proteins to Inhibit Type-I Interferon Signaling.Int J Mol Sci. 2024 Mar 28;25(7):3753. doi: 10.3390/ijms25073753. Int J Mol Sci. 2024. PMID: 38612565 Free PMC article.
-
A systematic review of SARS-CoV-2 vaccine candidates.Signal Transduct Target Ther. 2020 Oct 13;5(1):237. doi: 10.1038/s41392-020-00352-y. Signal Transduct Target Ther. 2020. PMID: 33051445 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous